These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 14652229)

  • 21. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
    Lipton A; Ali SM; Leitzel K; Demers L; Harvey HA; Chaudri-Ross HA; Brady C; Wyld P; Carney W
    J Clin Oncol; 2003 May; 21(10):1967-72. PubMed ID: 12743150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
    Ewertz M; Gray KP; Regan MM; Ejlertsen B; Price KN; Thürlimann B; Bonnefoi H; Forbes JF; Paridaens RJ; Rabaglio M; Gelber RD; Colleoni M; Láng I; Smith IE; Coates AS; Goldhirsch A; Mouridsen HT
    J Clin Oncol; 2012 Nov; 30(32):3967-75. PubMed ID: 23045588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [National Conference of Medical Oncology. Controversies in the treatment of breast cancer. Genova, October 28, 2000].
    Longo F
    Tumori; 2000; 86(6):A13-8. PubMed ID: 11271674
    [No Abstract]   [Full Text] [Related]  

  • 24. Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer.
    Ingle JN; Suman VJ; Jordan VC; Dowsett M
    Endocr Relat Cancer; 1999 Jun; 6(2):265-9. PubMed ID: 10731119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast cancer studies challenge tamoxifen therapy.
    Timms B
    Lancet Oncol; 2000 Nov; 1():132. PubMed ID: 11905647
    [No Abstract]   [Full Text] [Related]  

  • 26. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
    Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer.
    Piccart MJ; Cardoso F; Atalay G
    Eur J Cancer; 2002 Nov; 38 Suppl 6():S52-4. PubMed ID: 12409074
    [No Abstract]   [Full Text] [Related]  

  • 29. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
    Barnadas A; Estévez LG; Lluch-Hernández A; Rodriguez-Lescure A; Rodriguez-Sanchez C; Sanchez-Rovira P
    Adv Ther; 2011 Dec; 28(12):1045-58. PubMed ID: 22068628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Letrozole in breast cancer.
    Hietanen P; Mäkelä M
    N Engl J Med; 2004 Feb; 350(7):727-30; author reply 727-30. PubMed ID: 14971057
    [No Abstract]   [Full Text] [Related]  

  • 31. Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?
    Wu K; Brown P
    J Natl Cancer Inst; 2003 Jun; 95(11):766-7. PubMed ID: 12783921
    [No Abstract]   [Full Text] [Related]  

  • 32. Anastrozole data show continued delay in relapse, but no clear survival advantage.
    Travis K
    J Natl Cancer Inst; 2005 Jan; 97(2):86-7. PubMed ID: 15657334
    [No Abstract]   [Full Text] [Related]  

  • 33. [Superiority of letrozole compared with tamoxifen as first line therapy of postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group].
    Illiger HJ
    Strahlenther Onkol; 2002 Feb; 178(2):111-3. PubMed ID: 11942036
    [No Abstract]   [Full Text] [Related]  

  • 34. Aromatase inhibitors and inactivators in breast cancer.
    Lønning PE
    BMJ; 2001 Oct; 323(7318):880-1. PubMed ID: 11668120
    [No Abstract]   [Full Text] [Related]  

  • 35. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
    Ingle JN; Tu D; Pater JL; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Goss PE
    Breast Cancer Res Treat; 2006 Oct; 99(3):295-300. PubMed ID: 16541302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Letrozole: advancing hormone therapy in breast cancer.
    Lee RJ; Armstrong AC; Wardley AM
    Womens Health (Lond); 2012 Nov; 8(6):611-8. PubMed ID: 23181527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-operative endocrine therapy for postmenopausal women: when and why?
    Tondini C; Fenaroli P; Labianca R
    Ann Oncol; 2001 Nov; 12(11):1505-6. PubMed ID: 11822746
    [No Abstract]   [Full Text] [Related]  

  • 38. Current role of endocrine therapy in the management of breast cancer.
    Robertson JF
    Breast Cancer; 2002; 9(4):276-81. PubMed ID: 12459706
    [No Abstract]   [Full Text] [Related]  

  • 39. Extended adjuvant therapy with letrozole: reducing the risk of recurrence.
    Dixon JM
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):849-59. PubMed ID: 16761928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
    Nabholtz JM
    Am J Hosp Palliat Care; 2004; 21(6):457-65. PubMed ID: 15612238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.